文献速递胸部

分析型剂量引擎在肺癌调强质子治疗中是否足够?

Is an analytical dose engine sufficient for intensity modulated proton therapy in lung cancer?
PubMed 文献 · Br J Radiol · 2019-11-20

研究对20例肺癌患者的稳健优化调强质子治疗计划比较分析型剂量计算(ADC)与蒙特卡罗(MC)剂量计算,采用笔束(PB)与MC优化及最终剂量计算生成四种计划。PB-MC较PB-PB高估临床靶区99%剂量和平均剂量,γ通过率在D20和D99分别为93.2%和71.3%。存在纵隔病变且无距离移位器时ADC可能临床可接受,否则推荐MC算法。

要点

  • PB-MC较PB-PB高估临床靶区D99中位3.7 Gy(RBE)(5%)和平均剂量1.8 Gy(RBE)(3%)。
  • D20和D99的γ通过率(3%-3 mm)中位分别为93.2%和71.3%。
  • 存在纵隔病变且无距离移位器时ADC可能临床可接受,否则推荐MC算法。

诊断标准与关键数值

  • PB-MC较PB-PB高估临床靶区D99中位3.7 Gy(RBE)(5%)(范围2.3–6.9 Gy(RBE))和平均剂量中位1.8 Gy(RBE)(3%)(范围0.5–4.6 Gy(RBE))。
  • PB-MC scaled较PB-PB的CTVD2中位差异为-4 Gy(RBE)(-6%)(范围-5.3至-2.4 Gy(RBE)),p ≤ .001。
  • γ通过率(3%-3 mm)在D20和D99总体中位分别为93.2%(范围62.2–97.5%)和71.3%(范围15.4–92.0%)。
  • 多因素分析中,存在纵隔病变和无距离移位器与高γ通过率显著相关;具有这些预测因素时D20和D99通过率中位分别为96.0%(95.3–97.5%)和85.4%(75.1–92.0%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To identify a subgroup of lung cancer plans where the analytical dose calculation (ADC) algorithm may be clinically acceptable compared to Monte Carlo (MC) dose calculation in intensity modulated proton therapy (IMPT).

METHODS: Robust-optimised IMPT plans were generated for 20 patients to a dose of 70 Gy (relative biological effectiveness) in 35 fractions in Raystation. For each case, four plans were generated: three with ADC optimisation using the pencil beam (PB) algorithm followed by a final dose calculation with the following algorithms: PB (PB-PB), MC (PB-MC) and MC normalised to prescription dose (PB-MC scaled). A fourth plan was generated where MC optimisation and final dose calculation was performed (MC-MC). Dose comparison and γ analysis (PB-PB vs PB-MC) at two dose thresholds were performed: 20% (D20) and 99% (D99) with PB-PB plans as reference.

RESULTS: Overestimation of the dose to 99% and mean dose of the clinical target volume was observed in all PB-MC compared to PB-PB plans (median: 3.7 Gy(RBE) (5%) (range: 2.3 to 6.9 Gy(RBE)) and 1.8 Gy(RBE) (3%) (0.5 to 4.6 Gy(RBE))). PB-MC scaled plans resulted in significantly higher CTVD2 compared to PB-PB (median difference: -4 Gy(RBE) (-6%) (-5.3 to -2.4 Gy(RBE)), p ≤ .001). The overall median γ pass rates (3%-3 mm) at D20 and D99 were 93.2% (range:62.2-97.5%) and 71.3 (15.4-92.0%). On multivariate analysis, presence of mediastinal disease and absence of range shifters were significantly associated with high γ pass rates. Median D20 and D99 pass rates with these predictors were 96.0% (95.3-97.5%) and 85.4% (75.1-92.0%). MC-MC achieved similar target coverage and doses to OAR compared to PB-PB plans.

CONCLUSION: In the presence of mediastinal involvement and absence of range shifters Raystation ADC may be clinically acceptable in lung IMPT. Otherwise, MC algorithm would be recommended to ensure accuracy of treatment plans.

ADVANCES IN KNOWLEDGE: Although MC algorithm is more accurate compared to ADC in lung IMPT, ADC may be clinically acceptable where there is mediastinal involvement and absence of range shifters.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Teoh S, Fiorini F, George B, et al. Is an analytical dose engine sufficient for intensity modulated proton therapy in lung cancer? Br J Radiol. 2019. PMID: 31696729. doi:10.1259/bjr.20190583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。